The latest research result, the immune score test, can now more accurately define the disease progression of colon cancer patients. According to an international study of more than 2,500 patients, immune scores have been shown to be effective in predicting which patients have a high risk of tumor recurrence and can benefit from intensive treatment after surgery.
Ubukhulu bomdlavuza wekoloni kufanele bulinganiswe ngokuyisisekelo ngokusekelwe ekusabalaleni kwawo kanye ne-metastasis kukholoni. Lesi silinganiso sokuqina komdlavuza kanye nengozi yokuphinda futhi ngemva kokwelashwa kuzothuthukisa ukwelashwa. Sekungamashumi eminyaka, kukholakala ukuthi ukuphendula komzimba kweziguli kuzoba nomthelela omuhle kumdlavuza. Ucwaningo lwakamuva lukhombisa ukuthi ukuhlasela kwamangqamuzana omdlavuza ngamaseli omzimba kungaba yinkomba enhle yokukhomba indlela umdlavuza we-colorectal, kube yithuluzi lokubikezela elingaba khona lokuhlonza inani lamangqamuzana omzimba ngolwazi oluningi mayelana nokuqhubekela phambili kwesifo.
Ukwakhiwa kwalesi sivivinyo se-immunological kufanelekile ekwenzeni imitholampilo Isebenza ngokulinganisa ubukhulu bamaseli amabili omzimba ku-tumor kanye ne-margin yawo yokuhlasela: ama-T cell aphelele (CD3 +) namaseli weT killer (cytotoxic CD8 +). Lolu cwaningo luhlolisise inani lokubikezela leziguli ezinomdlavuza omkhulu kakhulu we-colon, kufaka phakathi iziguli ezingama-2681 ezivela ezikhungweni ezahlukahlukene. Ngokwengozi yokuphindeka (eminyakeni eyi-5 ngemuva kokuhlinzwa) kanye nokuhlolwa kwezinga lokusinda, iziguli zahlukaniswa zaba ngamaqembu amathathu (aphezulu, aphakathi nendawo kanye nezilinganiso zomzimba zokuzivikela ukubikezela ukusebenza kwesibikezelo. Imiphumela ikhombisa ukuthi iziguli ezinamazinga aphezulu wokuzivikela ezifweni ezethula ingozi ephansi kakhulu yokuphindeka nesikhathi esinde sokusinda.
Of the 700 patients, only 8% of patients with high scores relapsed after 5 years. However, the relapse rate of patients with middle and low scores increased significantly, reaching 19% and 32%, respectively. These findings indicate that the immune score provides an accurate and reliable assessment of the risk of colon cancer recurrence. Use the risk of recurrence to improve individual patient treatment strategies, especially changes in chemotherapy regimens. In view of the highly positive results of colon cancer, immunoscore tests for other cancers are under way, which will revolutionize the treatment of cancer patients.
